These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38366285)

  • 21. Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
    Alnaif A; Oiler I; D'Souza MS
    Ann Pharmacother; 2023 Aug; 57(8):956-965. PubMed ID: 36514282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.
    Stamatellos VP; Rigas A; Stamoula E; Lallas A; Papadopoulou A; Papazisis G
    Mult Scler Relat Disord; 2022 Mar; 59():103681. PubMed ID: 35168096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons from S1P receptor targeting in multiple sclerosis.
    Colombo E; Farina C
    Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?
    London F; Cambron B; Jacobs S; Delrée P; Gustin T
    Mult Scler Relat Disord; 2020 Jun; 41():102012. PubMed ID: 32088655
    [No Abstract]   [Full Text] [Related]  

  • 25. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract]   [Full Text] [Related]  

  • 26. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
    Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
    Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
    [No Abstract]   [Full Text] [Related]  

  • 27. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
    Hach T; Shakeri-Nejad K; Bigaud M; Dahlke F; de Micco M; Petricoul O; Graham G; Piani-Meier D; Turrini R; Brinkmann V; Nicoletti F
    J Interferon Cytokine Res; 2023 Jun; 43(6):246-256. PubMed ID: 36454249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
    Subei AM; Cohen JA
    CNS Drugs; 2015 Jul; 29(7):565-75. PubMed ID: 26239599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review.
    Li Q; Jing LJ; Li Y; Jia Y
    BMC Neurol; 2023 Jul; 23(1):286. PubMed ID: 37525104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T; Syed YY
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis.
    Tong J; Zou Q; Chen Y; Liao X; Chen R; Ma L; Zhang D; Li Q
    Neurol Sci; 2021 May; 42(5):1687-1695. PubMed ID: 33523319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.
    Ruggieri S; Quartuccio ME; Prosperini L
    Degener Neurol Neuromuscul Dis; 2022; 12():61-73. PubMed ID: 35356493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    Guerrieri S; Rubin M; Gattuso I; Zanetta C; Genchi A; Preziosa P; Rocca MA; Filippi M; Moiola L
    J Neurol; 2024 Jun; 271(6):3678-3681. PubMed ID: 38564055
    [No Abstract]   [Full Text] [Related]  

  • 38. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ; Cohen JA; Conway DS
    Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study.
    Al-Yafeai Z; Carvajal-González A; Abduljabar H; Arvas M; Patel S; Patel N
    Int J Cardiol; 2022 Sep; 362():153-157. PubMed ID: 35643216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.